FMP
Solid Biosciences Inc.
SLDB
NASDAQ
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
8.54 USD
-0.23 (-2.69%)
About
ceo
Mr. Alexander G. Cumbo
sector
Healthcare
industry
Biotechnology
website
https://www.solidbio.com
exchange
NASDAQ
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new ...
CIK
0001707502
ISIN
US83422E2046
CUSIP
83422E105
Address
141 Portland Street
Phone
617 337 4680
Country
US
Employee
88
IPO Date
Jan 26, 2018
Summary
CIK
0001707502
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
83422E105
ISIN
US83422E2046
Country
US
Price
8.54
Beta
1.94
Volume Avg.
264.34k
Market Cap
322.44M
Shares
-
52-Week
1.81-15.05
DCF
2.4
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.77
P/B
-
Website
https://www.solidbio.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest SLDB News
It looks like there's no news available.
